Story perspectives
FDA Fast-Tracks Merck Drugs Amid Legal Controversies
12/20/2025
1 of 1
Story summary
- The FDA granted national priority vouchers to Merck for Enlicitide and sac-TMT, expediting reviews to 1–2 months.
- This marks the 17th and 18th drugs in the fast-track program since its June launch.
- Enlicitide showed nearly 60% LDL reduction in a recent study, while sac-TMT targets various cancers.
- Concerns about legality and political influence arise as vouchers align with firms in price-reduction deals with the Trump administration.
